Antiviral therapy against chronic hepatitis B in Brazil: High rates of lamivudine resistance mutations and correlation with HBV genotypes

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 3, 2012, Pages 317-325

  Mello, Francisco Campello do Amaral ^a   Fernandes, Carlos Augusto ^b   Gomes, Selma de Andrade ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Laboratório Central de Saúde Pública Do Rio de Janeiro Noel Nutels LACEN RJ   (Brazil)

Author keywords

Antiviral drug resistance; HBV; Lamivudine; Therapy

Indexed keywords

ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; ENTECAVIR; GUANINE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; VIROLOGY; VIRUS LOAD;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; VIRAL LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84860250202     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000300005     Document Type: Article

References (56)

1. Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA 2004. High proportion of subgroup A' (genotype A) among Brazilian isolates of hepatitis B virus. Arch Virol 149: 1383-1395.
2. Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P 2007. Interferon therapy for chronic hepatitis B. Clin Liver Dis 11: 839-849.
3. Bhattacharya D, Thio CL 2010. Review of hepatitis B therapeutics. Clin Infect Dis 51: 1201-1208.
4. Bottecchia M, Ikuta N, Niel C, Araujo NM, OKycia MR, Gomes SA 2008a. Lamivudine resistance and other mutations in the polyme-rase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case. J Gastroenterol Hepatol 23: 67-72.
5. Bottecchia M, Souto FJ, O Kycia MR, Amendola M, Brandao CE, Niel C, Gomes SA 2008b. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 8: 11.
6. Cao GW 2009. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 15: 5761-5769.
7. Chu CM, Liaw YF 2005. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43: 411-417.
8. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP 2007. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 45: 1281-1328.
9. Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ 2001. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 36: 476-485.
10. Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL 2010. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 82: 1850-1858.
11. Delaney WET, Borroto-Esoda K 2008. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 8: 532-540.
12. Dienstag JL 2008. Hepatitis B virus infection. N Engl J Med 359: 1486-1500.
13. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341: 1256-1263.
14. Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S 2007. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol 79: 1664-1670.
15. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Haussinger D 2005. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54: 1009-1013.
16. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD 1999. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 180: 1757-1762.
17. Haddad R, Martinelli Ade L, Uyemura SA, Yokosawa J 2010. Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the city of Ribeirão Preto, state of São Paulo. Rev Soc Bras Med Trop 43: 224-228.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743-1751.
19. Kao JH, Chen PJ, Lai MY, Chen DS 2004. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 72: 363-369.
20. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F 2007. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5: 890-897.
21. Kramvis A, Kew MC 2005. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12: 456-464.
22. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 687-696.
23. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32: 828-834.
24. Liu CJ, Kao JH 2008. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 13: 613-624.
25. Lok AS, McMahon BJ 2007. Chronic hepatitis B. Hepatology 45: 507-539.
26. Mello FC, Souto FJ, Nabuco LC, Villela-Nogueira CA, Coelho HS, Franz HC, Saraiva JC, Virgolino HA, Motta-Castro AR, Melo MM, Martins RM, Gomes SA 2007. Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates. BMC Microbiol 7: 103.
27. Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvea MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE 2010. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. J Med Virol 82: 1481-1488.
28. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F 2003. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37: 1309-1319.
29. Moraes MT, Gomes SA, Niel C 1996. Sequence analysis of pre-S/S gene of hepatitis B virus strains of genotypes A, D and F isolated in Brazil. Arch Virol 141: 1767-1773.
30. Moraes MT, Niel C, Gomes SA 1999. A polymerase chain reaction-based assay to identify genotype F of hepatitis B virus. Braz J Med Biol Res 32: 45-49.
31. MS - Ministério da Saúde 2010. [homepage on the Internet]. Protocolo clínico e diretrizes terapêuticas para o tratamento da hepatite viral crônica B e co-infecções. Available from: portal.saude.gov.br/portal/arquivos/pdf/protocolo_hepatites.pdf.
32. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32: 1078-1088.
33. Nakayoshi T, Maeshiro T, Nakasone H, Sakugawa H, Kinjo F, Orito E, Mizokami M 2003. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J Med Virol 70: 350-354.
34. Orito E, Fujiwara K, Tanaka Y, Yuen MF, Lai CL, Kato T, Sugauchi F, Kusakabe A, Sata M, Okanoue T, Niitsuma H, Sakugawa H, Hasegawa I, Mizokami M 2006. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 35: 127-134.
35. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33: 218-223.
36. Pas SD, Niesters HG 2002. Detection of HBV DNA using real time analysis. J Clin Virol 25: 93-94.
37. Perrillo RP 1990. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 12: 1433-1435.
38. Pessoa MG, Gazzard B, Huang AK, Brandao-Mello CE, Cassetti I, Mendes-Correa MC, Soriano V, Phiri P, Hall A, Brett-Smith H 2008. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 22: 1779-1787.
39. Santos EA, Sucupira MV, Arabe J, Gomes SA 2004. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis 4: 29.
40. Sheldon J, Soriano V 2008. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61: 766-768.
41. Silva AC, Spina AMM, Lemos MF, Oba IT, Guastini CF, Gomes-Gouvea MS, Pinho JRR, Mendes-Correa MCJ 2010. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil. Mem Inst Oswaldo Cruz 105: 770-778.
42. Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ 2004. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol 42: 2455-2460.
43. Sucupira MVF, Mello FCA, Santos EA, Niel C, Rolla VC, Arabe J, Gomes SA 2006. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 101: 655-660.
44. Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spano A, Cappiello G, Perno CF 2009. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 50: 461-470.
45. Tamura K, Dudley J, Nei M, Kumar S 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
46. Teles SA, Martins RM, Gomes SA, Gaspar AM, Araujo NM, Souza KP, Carneiro MA, Yoshida CF 2002. Hepatitis B virus transmission in Brazilian hemodialysis units: serological and molecular follow-up. J Med Virol 68: 41-49.
47. Thompson JD, Higgins DG, Gibson TJ 1994. CLUSTALW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
48. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51: 2285-2292.
49. WHO - World Health Organization 2008. [homepage on the Internet]. Hepatitis B [revised 2008 August; cited 2011 april 5]. Available from: who.int/mediacentre/factsheets/fs204/en/.
50. Wiegand J, van Bömmel F, Berg T 2010. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis 30: 361-377.
51. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119: 312-323.
52. Yuen LK, Locarnini SA 2009. Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture. J Hepatol 50: 445-448.
53. Zhao SS, Tang LH, Dai XH, Wang W, Zhou RR, Chen LZ, Fan XG 2011. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virol J 8: 111.
54. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39: 42-50.
55. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH 2001. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357: 934-935.
56. Zoulim F, Locarnini S 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608.